VolitionRX Ltd (NYSEAMERICAN:VNRX) Sees Large Increase in Short Interest

VolitionRX Ltd (NYSEAMERICAN:VNRX) was the recipient of a significant growth in short interest in the month of October. As of October 15th, there was short interest totalling 441,000 shares, a growth of 43.1% from the September 15th total of 308,200 shares. Approximately 1.8% of the shares of the stock are sold short. Based on an average daily volume of 252,700 shares, the short-interest ratio is presently 1.7 days.

In other VolitionRX news, major shareholder Corp Ltd Eight sold 46,238 shares of the firm’s stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $6.03, for a total transaction of $278,815.14. Also, Director Martin Charles Faulkes bought 10,000 shares of the company’s stock in a transaction on Tuesday, August 27th. The shares were acquired at an average price of $3.75 per share, with a total value of $37,500.00. The disclosure for this purchase can be found here. Insiders purchased 110,000 shares of company stock valued at $532,000 in the last quarter.

A hedge fund recently raised its stake in VolitionRX stock. Morgan Stanley raised its holdings in shares of VolitionRX Ltd (NYSEAMERICAN:VNRX) by 15.4% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 94,350 shares of the medical research company’s stock after buying an additional 12,600 shares during the period. Morgan Stanley owned about 0.25% of VolitionRX worth $296,000 at the end of the most recent reporting period.

NYSEAMERICAN:VNRX traded down $0.11 during mid-day trading on Monday, hitting $5.84. 186,400 shares of the company’s stock traded hands, compared to its average volume of 138,090. VolitionRX has a 1 year low of $1.67 and a 1 year high of $6.84.

VolitionRX (NYSEAMERICAN:VNRX) last posted its earnings results on Monday, August 12th. The medical research company reported ($0.11) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.01.

About VolitionRX

VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. The company develops blood-based Nu.Q immunoassays to detect specific biomarkers. VolitionRX Limited is based in Singapore.

Recommended Story: Bollinger Bands

Receive News & Ratings for VolitionRX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VolitionRX and related companies with MarketBeat.com's FREE daily email newsletter.